Join the Oncology Voice Network. Join for Free
The Ideal Roadmap for New MSLs
Medical Science Liaisons MSL career progression personal branding digital presence MSL training

The Ideal Roadmap for New MSLs


Share This Article


Summary

In this episode, Tom Caravela is joined by Sarah Snyder, MSL Recruiter at The Carolan Group and Co-Founder of MSL Mastery who discusses an ideal road map for new Medical Science Liaisons (MSLs). They walk through the 4 stages of what a new MSL experiences in the first full year. Building the foundation in months 1 to 3, Gaining momentum in months 3-6, becoming a trusted partner in months 6-12 and driving impact/delivering results at the 1 year mark and beyond. They also discuss tools and resources for enhancing MSL career progression and development. The episode explores personal branding, social media presence, and future trends in digital as well as AI for MSLs.

Key Points

  • Establishing a well-organized home office and staying updated in your therapeutic area is crucial for new MSLs to hit the ground running.
  • Building a strong foundation through structured training and certification is essential in the initial months to set the stage for becoming a trusted partner in the field.
  • Personal branding and maintaining a professional digital presence on platforms like LinkedIn are increasingly important for career advancement and networking as an MSL.

Click for Source
Medical Science Liaisons, MSL career progression, personal branding, digital presence, MSL training

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Promotability: How to Land Your Next Promotion
Partner Avatar Tom Caravela

Promotability: How to Land Your Next Promotion

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN